Mensali, Nadia http://orcid.org/0000-0002-3130-4352
Myhre, Marit Renée
Dillard, Pierre http://orcid.org/0000-0002-4812-9159
Pollmann, Sylvie
Gaudernack, Gustav http://orcid.org/0000-0002-9678-7447
Kvalheim, Gunnar http://orcid.org/0000-0001-5148-2941
Wälchli, Sébastien http://orcid.org/0000-0001-5869-1746
Inderberg, Else Marit http://orcid.org/0000-0002-6147-3536
Funding for this research was provided by:
Norwegian Health Region South East (2010021)
Norwegian Research Council (244388, 254817)
Norwegian Ministry of Health (Gene Therapy Grant)
Article History
Received: 2 December 2018
Accepted: 7 June 2019
First Online: 18 June 2019
Change Date: 27 November 2019
Change Type: Correction
Change Date: 27 November 2019
Change Type: Correction
Change Details: The original version of this article unfortunately included a mistake in Fig. 2b where the images of mice in the tumour control group (right), day 30 (bottom) should be removed as the wrong images (duplicate of day 17) were inserted by mistake. At this time point the tumour control mice were no longer alive and the images were replaced by black areas.
Change Details: The original version of this article unfortunately included a mistake in Fig.��2b where the images of mice in the tumour control group (right), day 30 (bottom) should be removed as the wrong images (duplicate of day 17) were inserted by mistake. At this time point the tumour control mice were no longer alive and the images were replaced by black areas.
Compliance with ethical standards
:
: G. Gaudernack, G. Kvalheim, S. Wälchli and E.M. Inderberg are inventors of the patent WO2017194555. No potential conflicts of interest were disclosed by the other authors.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee. Healthy donor T cells were obtained from buffy coats from the Blood bank under informed consent. The study was approved by the Regional Committee for Medical Research Ethics (REC approval reference number 2011/856) Oslo, Norway. All mouse experiments were conducted under the Institutional Animal Care and Norwegian Food Safety Authority-approved protocols (Approval ID: 4520). All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
: NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ(NSG) mice were bred in-house.
: The colon cancer cell line HCT 116 was purchased from ATCC. Commercially available human cell line identities were verified using short tandem repeat profiling. EBV-LCLs were generated in-house by transformation of healthy donor B cells as described. Cell lines were tested for mycoplasma contamination using a PCR based detection kit (Venor®GeM, Minerva Biolabs).